Jump to content

Neomycin/polymyxin B/hydrocortisone

This article's lead is ready for translation. Click for more information.
From WikiProjectMed
Neomycin/polymyxin B/hydrocortisone
Combination of
NeomycinAntibiotic
Polymyxin BAntibiotic
HydrocortisoneGlucocorticoid
Names
Trade namesOtosporin, Cortisporin, others
Clinical data
Pregnancy
category
Routes of
use
Ear drop, ear drop
Defined daily dosenot established[2]
External links
AHFS/Drugs.comFDA Professional Drug Information
Legal
Legal status


Neomycin/polymyxin B/hydrocortisone, sold under the brand Otosporin among others, is a medication used to treat otitis externa (swimmer's ear) and certain eye disorders.[3][4] It consists of the antibiotics neomycin and polymyxin B, and the steroid hydrocortisone.[4] It is used as an ear drop or eye drop.[3][4]

The most common side effects include itchiness and a skin rash.[5] Other side effects may include dizziness, hives, anaphylaxis, hearing loss, and headache.[3][5] Safety in pregnancy and breastfeeding is unclear.[1] The antibiotics work by killing specific types of bacteria while the steroids work by decreasing inflammation.[6]

The combination was approved for medical use in the United States in 1964.[4] In the United Kingdom a 10 ml bottle costs the NHS about £7.45 as of 2019.[3] In the United States the wholesale cost of this amount is about US$50.[7] In 2017, it was the 304th most commonly prescribed medication in the United States, with more than one million prescriptions.[8]

Medical uses

Dosage

The defined daily dose is not established[2]

History

Cortisporin was developed by Glaxo Wellcome and was approved by the Food and Drug Administration in 1975. In 1997, the rights were sold to Monarch Pharmaceuticals, a division of King Pharmaceuticals. In 2007, King sold it to JHP Pharmaceuticals. Par Pharmaceutical acquired JHP in 2014. In 2015, Endo International purchased Par.[9]

Society and culture

Cost

In David Lazarus' February 4, 2016 LA Times column, a pharmacist recalled a 10 milliliter vial of the drug selling for around $10 in the early 2010s. In 2015, the price was $100, and in 2016, it reportedly was selling for $195. A generic version is priced at $144.[9] The drug is owned by Dublin, Ireland-based Endo International.

Formulations

Generic name: neomycin sulfate, polymyxin B sulfate, and hydrocortisone
Dosage form: otic suspension (liquid with ear dropper)
Generic name: neomycin sulfate, polymyxin B sulfate, bacitracin zinc and hydrocortisone
Dosage form: Dermatological ointment, drops

References

  1. 1.0 1.1 "Hydrocortisone / neomycin / polymyxin b otic Use During Pregnancy". Drugs.com. Archived from the original on 19 April 2019. Retrieved 19 April 2019. Archived 19 April 2019 at the Wayback Machine
  2. 2.0 2.1 "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 1 July 2021. Retrieved 9 September 2020. Archived 1 July 2021 at the Wayback Machine
  3. 3.0 3.1 3.2 3.3 British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 1164. ISBN 9780857113382.
  4. 4.0 4.1 4.2 4.3 "Neomycin, Polymyxin B, Hydrocortisone Ophthalmic Suspension - FDA prescribing information, side effects and uses". Drugs.com. Archived from the original on 20 June 2019. Retrieved 19 April 2019. Archived 20 June 2019 at the Wayback Machine
  5. 5.0 5.1 "Hydrocortisone/neomycin/polymyxin b otic Side Effects in Detail". Drugs.com. Archived from the original on 19 April 2019. Retrieved 19 April 2019. Archived 19 April 2019 at the Wayback Machine
  6. "DailyMed - neomycin sulfate, polymyxin b sulfate and hydrocortisone solution". dailymed.nlm.nih.gov. Archived from the original on 26 June 2020. Retrieved 19 April 2019. Archived 26 June 2020 at the Wayback Machine
  7. "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Archived from the original on 2019-03-06. Retrieved 3 March 2019. Archived 2019-03-06 at the Wayback Machine
  8. "Neomycin; Polymyxin B; Hydrocortisone - Drug Usage Statistics". ClinCalc. Archived from the original on 12 April 2020. Retrieved 11 April 2020. Archived 12 April 2020 at the Wayback Machine
  9. 9.0 9.1 Lazarus, David (2016-02-04). "Martin Shkreli isn't alone in ripping off patients with crazy drug prices". latimes.com. Archived from the original on 2019-12-30. Retrieved 2016-02-05. Archived 2019-12-30 at the Wayback Machine

External links

Identifiers: